HomeArticle

With an upfront payment of 330 million US dollars, why did Pfizer place a bet on China's innovative drugs in advance?

知产力2026-11-19 18:32
On November 18, Pfizer announced that it has entered into an exclusive licensing agreement with China's StarRise Medicine.

Pfizer has committed to paying a $330 million upfront payment for three projects that are still in the pre-IND filing stage.

More notably, Pfizer has simultaneously obtained the right to use the relevant technologies, and reserved options for subsequent research achievements and the Greater China market.

This transaction not only prices existing R&D achievements, but also arranges the distribution of future results in advance.

On November 18, Pfizer announced that it has reached an exclusive licensing agreement with China's Starna Therapeutics. In addition to the upfront payment, Starna may also receive up to $2.3 billion in development and commercial milestone payments, as well as royalties on net sales of approved products. The three licensed projects are all in vivo CAR-T projects targeting autoimmune diseases, and Pfizer has obtained the exclusive rights to develop, manufacture and commercialize them outside Greater China.

Founded in 2021, Starna Therapeutics focuses on extrahepatic targeted delivery technology to develop RNA-centered drugs. Its technical foundation involves how to deliver RNA to specific tissues and cells to perform its expected functions.

For enterprises like this, projects and platforms have different commercial implications: one project strives to become a drug, while the platform may support multiple projects. This agreement happens to involve both levels at the same time.

The key to early-stage transactions is to price uncertainties in stages.

The three projects still have a long way to go before they hit the market. Clinical efficacy, safety, production and regulatory approval all require further verification. Pfizer's willingness to pay the upfront payment is a commercial investment decision, but it cannot replace these verifications.

For buyers, waiting until all risks are significantly reduced before participating in the competition may require paying a higher price, or even losing the opportunity to obtain the projects.

Entering in advance means taking more R&D risks; correspondingly, there is also the opportunity to obtain exclusive rights earlier and integrate the projects into its own development system.

Upfront payments, milestones and sales royalties are exactly the tools to distribute risks and benefits in this process. The upfront payment provides consideration for obtaining the agreed rights; whether subsequent milestones can be realized depends on whether the agreed conditions are met; sales royalties give the licensor the opportunity to continue to participate in the distribution of benefits after the product is launched.

Therefore, "up to 2.63 billion US dollars" cannot be directly regarded as realized revenue, nor can it be simply divided by three to calculate the price of each project.

The most noteworthy part to break down is the four layers of rights in the agreement.

The first layer is the exclusive rights of the three projects outside Greater China. This determines in which markets Pfizer can develop and operate the related products.

The second layer is the right to use Starna's proprietary in vivo CAR-T technology in the fields of inflammation, immunology and oncology. This extends the cooperation to the technical capability itself, but it cannot be concluded that the ownership of the platform has been transferred, nor can this right of use be automatically interpreted as an exclusive license covering all fields.

The third layer is the option to obtain an exclusive license for compounds generated from separate research collaborations.

The fourth layer is the option to extend the development and commercialization rights of the relevant licensed compounds and products to Greater China. This is still an option, not a representation that Pfizer has obtained global exclusive rights.

Putting these layers together, we can see the commercial depth of the transaction: existing projects provide a starting point, technology use rights expand R&D possibilities, and subsequent achievements and regional options reserve paths for further cooperation.

Among them, the option is particularly worthy of attention for Chinese enterprises.

Its value lies in that the two parties agree on a mechanism for obtaining a certain right in the future now, reducing the uncertainty of renegotiation at that time. For the buyer, this may help it make investment decisions after seeing more R&D results; for the seller, making such arrangements in advance may also affect the space for licensing to other partners in the future.

The exact impact depends on the term, trigger conditions, exercise price and relevant restrictions of the option. These details have not been made public, so it is impossible to judge how the two parties price specifically, let alone assert that one party has taken advantage.

But one thing is certain: the option itself is a transaction content that requires serious valuation, and cannot be regarded as an insignificant ancillary clause beyond the upfront payment.

What Chinese enterprises obtain is not just capital.

According to Pfizer's announcement, it will lead clinical development outside Greater China and plans to use U.S. facilities to manufacture the finished drug products required for initial clinical trials.

This means that the cooperation between the two parties will further move from technical achievements to the development and manufacturing system.

For early-stage R&D enterprises, independently completing multi-region clinical trials, production scale-up and commercialization requires continuous investment and organizational capabilities. Cooperating with partners with corresponding resources can enable R&D achievements to obtain greater promotion conditions.

The value of international licensing is formed in this combination of capabilities. We should not simply interpret the transaction as technology loss just because overseas rights are granted to partners; nor should we assume that all long-term value has been fully compensated just because the upfront payment is considerable.

To evaluate a transaction, we need to look at both what has been obtained and what has been committed for it.

In particular, platform-based enterprises must distinguish between existing platform technologies, specific project achievements, and improvements formed during the cooperation. Even if the ownership of the platform is retained, the specific scope of use, exclusive arrangements and future achievement clauses may still affect the subsequent operating space.

The real test of negotiation capability is to make each layer of rights have clear boundaries.

Which technologies can continue to serve other projects? Who owns and can use the improvements generated from the cooperation? How long can future options be retained? How will the rights be handled if the project is stagnant for a long time?

These are the issues that need to be addressed in platform licensing, and do not mean that this agreement has adopted a specific arrangement. The full contract has not been made public, and the outside world cannot fill in the clauses for the two parties.

But for more Chinese enterprises preparing to carry out overseas licensing, this transaction provides a clear reminder: Negotiations cannot only focus on "how much more the upfront payment can be increased", but also calculate the distribution of future cooperation opportunities.

Transactions with a wide exclusive scope and many options cannot be directly compared only by the amount with transactions that only license a clear specific project. The technology source, the scope of patents and proprietary technologies, the ownership of R&D achievements, promotion obligations and exit arrangements jointly determine the actual value of a license.

The cooperation between Starna and Pfizer demonstrates a way for Chinese R&D enterprises to participate in the international division of labor: enter the cooperation with early-stage projects, expand the cooperation with technical capabilities, and participate in future revenues through staged payments.

Whether this transaction can be fulfilled still needs to be tested by R&D, clinical and commercialization practices. But it has raised a more worthy of discussion issue than "large-value licensing":

When a Chinese enterprise can continuously generate new achievements, what it needs to price is not just the three projects it presents today, but also the future opportunities formed around these capabilities.

This article is from the WeChat Official Account "Zhichanli" (ID: zhichanli), written by Shawn/MCP, and authorized for release by 36Kr.